The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Association of baseline and on-treatment ctDNA fraction with clinical outcomes in patients with mCRPC in the PSMAfore study of 177Lu-PSMA-617.
 
Johann De Bono
Honoraria - Amgen; Astellas Pharma; AstraZeneca; Bayer; Daiichi Sankyo; Genentech/Roche; GlaxoSmithKline; ImCheck therapeutics; Janssen Oncology; Merck Serono; Merck Sharp & Dohme; Pfizer; Sanofi
Consulting or Advisory Role - Abbvie; Acai Therapeutics; Amgen; Amunix (Inst); Astellas Pharma; AstraZeneca; Bayer; BioXCel therapeutics (Inst); Boehringer Ingelheim (Inst); CellCentric; Crescendo Biologics (Inst); Daiichi Sankyo; Dark Blue Therapeutics (Inst); Eisai; Genentech/Roche; Genmab; GlaxoSmithKline; Harpoon therapeutics; ImCheck therapeutics; Immunic Therapeutics; Janssen Oncology; Merck Serono; Merck Sharp & Dohme; MetaCurUm; Myricx Pharma; Novartis; Nurix (Inst); Oncternal Therapeutics; Orion; Pfizer (Inst); Qiagen; Sanofi Aventis GmbH (Inst); Sierra Oncology; Taiho Oncology; Takeda (Inst); Tango Therapeutics (Inst)
Speakers' Bureau - AstraZeneca
Research Funding - Amgen (Inst); AstraZeneca (Inst); CellCentric (Inst); Crescendo Biologics (Inst); Daiichi Sankyo (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Immunic Therapeutics (Inst); Janssen (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); MetaCurUm (Inst); MorphoSys (Inst); Myricx (Inst); Nurix (Inst); Oncternal Therapeutics (Inst); Orion (Inst); Pfizer (Inst); Sanofi Aventis GmbH (Inst); Taiho Pharmaceutical (Inst)
Patents, Royalties, Other Intellectual Property - Abiraterone Rewards to Inventors (Inst); CHK1 inhibitor (Inst); PARP inhibitors and DNA repair defects (Inst); Targeting of IL23 in prostate cancer (Inst)
Travel, Accommodations, Expenses - Amgen; Astellas Pharma; AstraZeneca; Bayer; Cellcentric; Daiichi Sankyo; Genentech/Roche; GlaxoSmithKline; Halda Therapeutics; Merck Serono; Merck Sharp & Dohme; Orion; Pfizer; Sanofi
 
Michael Morris
Employment - Memorial Sloan-Kettering Cancer Center
Stock and Other Ownership Interests - Doximity
Consulting or Advisory Role - Ambrx; Arvinas; AstraZeneca; Blue Earth Diagnostics; Bristol-Myers Squibb/Celgene; Clarity Pharmaceuticals; Convergent Therapeutics; Core Medica; Curium Pharma; Daiichi; Exelixis; Flare Therapeutics; Fusion Pharmaceuticals; ITM Isotope Technologies Munich; Lantheus Medical Imaging; Mashup Media; Pfizer; POINT Biopharma; Progenics; Telix Pharmaceuticals; Transtherabio; Z-Alpha
Research Funding - Astellas Pharma (Inst); Celgene (Inst); Corcept Therapeutics (Inst); Janssen (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - Novartis (Inst); Telix Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - Amgen; APCCC; AstraZeneca; Memorial Sloan-Kettering Cancer Center
(OPTIONAL) Uncompensated Relationships - Amgen; Amgen; Bayer; Janssen Oncology; Novartis
 
Alton Sartor
Stock and Other Ownership Interests - Abbott Laboratories; Abbvie; Cardinal Health; Clarity Pharmaceuticals; Convergent Therapeutics; Fusion Pharmaceuticals; Lilly; POINT Biopharma; PSMA Therapeutics; Ratiopharm; Telix Pharmaceuticals; United Health Group
Honoraria - Intellisphere; Lantheus Medical Imaging; Novartis
Consulting or Advisory Role - Advanced Accelerator Applications; Amgen; ARTbio; Astellas Pharma; AstraZeneca; Bavarian Nordic; Bayer; Blue Earth Diagnostics; Bristol-Myers Squibb; Clarity Pharmaceuticals; Clovis Oncology; Constellation Pharmaceuticals; Dendreon; EMD Serono; Fusion Pharmaceuticals; Hengrui Therapeutics; Isotopen Technologien; Janssen; MacroGenics; Medscape; Merck; Morphimmune; Myovant Sciences; Myriad Genetics; Noria Therapeutics; Northstar; Novartis; Noxopharm; Pfizer; Point Biopharma; Progenics; Ratio; Sanofi; Telix Pharmaceuticals; TEmpus; TeneoBio; Tessa Therapeutics; Theragnostics
Research Funding - Advanced Accelerator Applications (Inst); Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); Constellation Pharmaceuticals (Inst); Dendreon (Inst); Endocyte (Inst); InVitae (Inst); Janssen; Lantheus Medical Imaging (Inst); Merck (Inst); Progenics; Sanofi (Inst); SOTIO
Patents, Royalties, Other Intellectual Property - Koochekpour, Sartor AO, inventors. Saposin C and receptors as targets for treatment of benign and malignant disorders. US patent awarded January 23, 2007 (patent no. 7,166,691).
Expert Testimony - Sanofi
Travel, Accommodations, Expenses - AstraZeneca; Bayer; Johnson & Johnson; Lantheus Medical Imaging; Progenics; Sanofi
 
Xiao Wei
Honoraria - OncLive
Consulting or Advisory Role - Dendreon; Novartis; Novartis; Novartis; Novartis
Research Funding - Bristol-Myers Squibb (Inst)
Travel, Accommodations, Expenses - Corvus Pharmaceuticals; Novartis
 
Karim Fizazi
Honoraria - Astellas Pharma (Inst); Bayer (Inst); Janssen (Inst)
Consulting or Advisory Role - Amgen (Inst); Arvinas; Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); CureVac; Daiichi Sankyo Europe GmbH (Inst); Janssen Oncology (Inst); Macrogenics; MSD (Inst); Novartis (Inst); Orion; Pfizer (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Janssen; MSD; Pfizer
 
Ken Herrmann
Leadership - Aktis Oncology; Pharma15
Stock and Other Ownership Interests - AdvanCell; Aktis Oncology; Convergent Therapeutics; SOFIE
Consulting or Advisory Role - Advanced Accelerator Applications; Amgen; AstraZeneca; Bain Capital; Bayer; Boston Scientific; BTG; Debiopharm Group; Fusion Pharmaceuticals; GE Healthcare; Immedica; IPSEN; ITG (Inst); Janssen Oncology; Molecular Partners; Novartis; Radiopharm Theranostics; ROTOP Pharmaka (Inst); Siemens Healthineers; Telix Pharmaceuticals
 
Josep Piulats
Consulting or Advisory Role - Astellas Pharma; AstraZeneca/MedImmune; BeiGene; Bristol-Myers Squibb; Clovis Oncology; IDEAYA Biosciences; Immunocore; Janssen Oncology; Merck Sharp & Dohme; Pfizer; Roche/Genentech; VCN Biosciences
Research Funding - AstraZeneca/MedImmune; BeiGene; Bristol-Myers Squibb; Immunocore; Incyte; Janssen Oncology; Merck Sharp & Dohme; Mirati Therapeutics; Pfizer/EMD Serono
Travel, Accommodations, Expenses - AstraZeneca Spain; Bristol-Myers Squibb; Janssen Oncology; Pfizer; Roche
 
Hakim Mahammedi
Honoraria - AAA/Endocyte/Novartis; Astellas Pharma; Bayer Schering Pharma; BMS GmbH & Co. KG; Curium Pharma; Eisai; ipsen; Janssen Oncology; Merck Serono; MSD Oncology; Novartis; Pfizer/EMD Serono
Travel, Accommodations, Expenses - AAA/Endocyte/Novartis; Bayer Schering Pharma; Bayer Schering Pharma; Eisai; IPsen; Janssen Oncology; Pfizer
Other Relationship - Curium Pharma
 
Christopher Logothetis
Honoraria - AADi; Amgen; Boehringer Pharma GmbH; GlaxoSmithKline; Janssen Scientific Affairs
Research Funding - Aragon Pharmaceuticals (Inst); Janssen; Novartis (Inst); ORIC Pharmaceuticals (Inst)
 
Daniel George
Leadership - Capio BioSciences
Honoraria - American Association for Cancer Research; AstraZeneca; Aveo; Axess Oncology; Bayer; Eisai; EMD Serono; Exelixis; IDEOlogy Health; Janssen Oncology; Medscape; Merck; Millennium Medical Publishing; Myovant Sciences; Nektar; Novartis; OncLive; Pfizer; Propella Therapeutics; Sanofi; Seagen; UroToday
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Constellation Pharmaceuticals; Exelixis; Janssen; Merck Sharp & Dohme; Michael J. Hennessy Associates; Myovant Sciences; Novartis; Pfizer; Physicans' Education Resource; Propella Therapeutics; RevHealth; Sanofi; Xcures
Speakers' Bureau - Bayer; Exelixis; Sanofi
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Corvus Pharmaceuticals (Inst); Dendreon (Inst); Exelixis (Inst); Janssen Oncology (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Sanofi/Aventis (Inst)
Expert Testimony - Exelixis
Travel, Accommodations, Expenses - Bayer; Exelixis; Novartis; Pfizer
 
Connie Wong
Employment - Novartis
Stock and Other Ownership Interests - Novartis
Patents, Royalties, Other Intellectual Property - Novartis
 
Louise Barys
Employment - Novartis
Stock and Other Ownership Interests - Novartis
 
Nisha Rajagopal
Employment - LifeMine Therapeutics (I); Novartis; SERVIER (I); Syros Pharmaceuticals
Stock and Other Ownership Interests - LifeMine Therpeutics (I); Novartis Biociencias; SERVIER (I); Syros Pharmaceuticals
Patents, Royalties, Other Intellectual Property - Syros Pharmaceuticals
Travel, Accommodations, Expenses - LifeMine Therapeutics (I); Novartis; SERVIER (I); Syros Pharmaceuticals
Other Relationship - LifeMine Therapeutics (I); Novartis; SERVIER (I); Syros Pharmaceuticals
 
Shaheen Alanee
Employment - Novartis
Stock and Other Ownership Interests - Novartis
 
Kim Chi
Honoraria - Amgen; Astellas Pharma; AstraZeneca; Bayer; BMS GmbH & Co. KG; BMS GmbH & Co. KG; Janssen; Merck; Novartis; Pfizer; POINT Biopharma; Roche
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; Janssen; Merck; POINT Biopharma; Roche
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); ESSA (Inst); Janssen (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Sanofi (Inst)